A Phase I/II study of Horama's drug candidate HORA-PDE6B for the treatment of patients with retinitis pigmentosa was authorized by the French National Agency for Medicines and Health Products Safety. The study will evaluate the safety and efficacy of the drug in patients with retinitis pigmentosa brought by biallelic mutations in the PDE6B gene.
Horama authorized by French regulator to launch retinitis pigmentosa drug study
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.